Pico IV, makers of the only sterile CBD solution for IV Infusions, will begin clinical trials to better understand the benefits, and REDCap Cloud will help get them there.
SACRAMENTO, March 12, 2024
When Pico IV first launched in 2023, it created new possibilities for both the hemp and wellness industries. Joe Young, CEO, and Miles Terry, CSO, have several years of experience in the hemp industries and nanotechnology. Their passion about using technology to improve the use and access to various cannabinoids led to creation of patent-pending technology that can manufacture a sterile CBD IV solution. Since its release, CBD IV therapy has brought many benefits of cannabidiol and the hemp world to IV Therapy Clinics across the country.
Pico IV is now available in 183 clinics across 35 states. The intravenous (IV) hydration therapy market has experienced tremendous growth in the last decade and is projected to continue growing over the coming years. Pico IV offers the opportunity to supplement the already popular IV treatments with the unique benefits of CBD, allowing IV Therapy to create custom protocols for their customers.
As more and more users have tried out CBD IV Therapy for themselves, it has become clear the known benefits of CBD are being magnified in an intravenous use case. In order to better understand the effects and benefits of this novel wellness product, Pico IV is partnering with Red Cap Cloud to advance the studies and make use of their best-in-class data collection & management. To begin, these clinical studies will focus on select conditions, including auto-immune diseases, such as Crohn’s disease, Lyme disease and Ulcerative Colitis. In addition, Pico IV Inc. is sponsoring a study under an IRB for cancer patients under the supervision of Dr. Nathan Goodyear, M.D, MD(H), ABAARM, FMNM.**
“We are so thrilled to start the process of clinical trials, and to do it with excellence,” said Joe Young, CEO of PICO IV Inc. “Choosing the right company to help us with the data collection and management was crucial. In the last few months, we’ve seen how many people have been positively impacted by CBD IV therapy. We hope these clinical studies will bring further clarity and understanding of the power of CBD and hemp.”
Red Cap Cloud powers data-driven digital research to accelerate medical discoveries, connect research and care, and establish new standards of scientific innovation based on real-world evidence. Their unique software will provide the ability to convert data to a common format supporting advanced real-world evidence analysis, reporting, and dashboards.
Together, Pico IV and REDCap Cloud will explore the potential benefits of CBD IV therapy while upholding the most rigorous scientific standards and data management.
ABOUT PICO IV Inc.:
Founded in 2023, PICO IV Inc pioneered a new technology to become the world’s first manufacturer of CBD IV Therapy. Committed to using the highest quality CBD with rigorous third-party testing, Pico IV sets the standard for CBD quality, transparency, and efficacy. PICO IV is currently available in a number of clinics across the US and is available for purchase by licensed providers. For more information, please visit PicoIV.com
About nPhase | REDCap Cloud
REDCap Cloud empowers patient-centered clinical research to advance discoveries, commercialize therapeutics and devices, and establish new standards of care based on real-world evidence. Through its REDCap Cloud suite of products and services, nPhase serves clients and partners worldwide including life science companies, contract research organizations (CROs), academic research centers, integrated health systems, government agencies, and foundations. REDCap Cloud is a unified data management platform to collect, manage, analyze, and share data to make the right decisions at the right time. For more information, please visit https://www.redcapcloud.com.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
**IRB HHS Registration IRB00014230, PicoIV IRB #1- Cannabidiol-Cancer